Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
40 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Prevention
Participants needed
2,000 (estimated)
Sponsor
Stanford University · Other
Who this trial is looking for
This trial is looking for people who have had a stroke or mini-stroke within the last 6 months. Participants will take a medication called cilostazol or a placebo and be monitored for up to 5 years to see if it helps prevent further strokes or heart attacks.
Are You a Good Fit for This Trial?
Must be takingAspirinClopidogrelTicagrelor
You may be able to join if
I am 40 years old or older.
I have had an ischemic stroke or a high-risk mini-stroke.
I can start this trial within 180 days after my stroke or mini-stroke.
I am taking medication as advised by my healthcare provider.
I have two or more risk factors for strokes, like being older or having high blood pressure.
I am medically stable and can attend follow-up appointments.
I can receive the study drug by mail.
I have signed the informed consent form.
You may not be able to join if
I have atrial fibrillation or a mechanical heart valve.
I have had a serious brain bleed in the last 2 years.
I am pregnant, breastfeeding, or not using birth control.
I have severe liver problems.
I am enrolled in another clinical study.
I have heart failure with current symptoms.
I expect to live less than 6 months.
I do not allow my healthcare provider to share health information if needed.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
The goal of this clinical study is to learn if adding a medicine called cilostazol to usual treatment can help prevent another stroke, a heart attack, or death in patients who had a stroke caused by a blocked blood vessel, or a "mini-stroke" (also called a TIA), in the past 6 months.
To determine if cilostazol is safe and effective at lowering the chance of strokes, heart attacks and deaths, the …
The goal of this clinical study is to learn if adding a medicine called cilostazol to usual treatment can help prevent another stroke, a heart attack, or death in patients who had a stroke caused by a blocked blood vessel, or a "mini-stroke" (also called a TIA), in the past 6 months.
To determine if cilostazol is safe and effective at lowering the chance of strokes, heart attacks and deaths, the study will compare cilostazol to a placebo, a pill that looks the same as cilostazol but has no medicine in it.
Participants will:
* Be assigned by chance to take either cilostazol or a placebo, along with their usual medicine.
* Not know which one they are taking, and neither will the study team, which keeps the results fair.
* Be followed for up to 5 years to see if they have a stroke, heart attack, or major bleeding.
See the Clarity study website for more information:
https://www.claritystrokestudy.org/
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
1. ≥40 years
2. Ischemic stroke or high-risk TIA (ABCD2 score ≥6)
3. Can be randomized within 180 days after ischemic stroke or high-risk TIA
4. Treatment with single or dual antithrombotic therapy with aspirin, clopidogrel and/or ticagrelor per international and/or national gui…
Inclusion Criteria:
1. ≥40 years
2. Ischemic stroke or high-risk TIA (ABCD2 score ≥6)
3. Can be randomized within 180 days after ischemic stroke or high-risk TIA
4. Treatment with single or dual antithrombotic therapy with aspirin, clopidogrel and/or ticagrelor per international and/or national guidelines
5. Two or more of the following risk factors: age 65 years or older, hypertension, diabetes mellitus, history of ischemic stroke other than the qualifying event for this trial, currently smoking, peripheral arterial disease, coronary artery disease including prior MI, aortic atherosclerotic plaque ≥4 mm, ≥50% stenosis or occlusion of a major intracranial artery (ICA, M1, M2, A1, P1, vertebral, or basilar) or extracranial artery (ICA or vertebral)
6. In the opinion of the site investigator, patient is medically stable, capable of participating in the trial, and willing and able to attend follow-up
7. Able to receive study drug by mail and able to begin taking study drug promptly after receipt
8. Provision of signed and dated informed consent form by patient or legally authorized representative
Exclusion Criteria:
1. Atrial fibrillation, mechanical heart valve, or left ventricular assist device
2. Use of prohibited medication (as specified in the MOP)
3. Modified Rankin Scale 5
4. Planned cardiac surgery, percutaneous coronary intervention, carotid endarterectomy or stenting (patients are eligible post-procedure)
5. History of symptomatic non-traumatic intracerebral hemorrhage within last 2 years
6. Known thrombocytopenia (platelet count ≤100,000 per microliter (µL))
7. Severe liver dysfunction (active hepatitis or hepatic insufficiency with Child-Pugh score B or C)
8. Pregnant, breast-feeding, or of child-bearing potential but not on birth control
9. Confirmed diagnosis of heart failure with current or prior symptoms or signs (e.g. paroxysmal nocturnal dyspnea, reduced exercise tolerance, ankle swelling, elevated jugular venous pressure)
10. Hypersensitivity to cilostazol or any component of the formulation (e.g. anaphylaxis, angioedema)
11. Currently enrolled in an investigational intervention study
12. Life expectancy less than 6 months
13. Participant does not allow contacting of their surrogate (e.g. family member or friend) or health care practitioner to obtain health information should participant become unwilling or unable to follow the study schedule.
14. Participants who are incarcerated, including prisoners or participants compulsorily detained for treatment of psychiatric disease.
Contacts
No contact information available.
What are you hoping to find?
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.